Literature DB >> 9727886

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections.

H King1, R E Aubert, W H Herman.   

Abstract

OBJECTIVE: To estimate the prevalence of diabetes and the number of people with diabetes who are > or =20 years of age in all countries of the world for three points in time, i.e., the years 1995, 2000, and 2025, and to calculate additional parameters, such as sex ratio, urban-rural ratio, and the age structure of the diabetic population. RESEARCH DESIGN AND METHODS: Age-specific diabetes prevalence estimates were applied to United Nations population estimates and projections for the number of adults aged > or =20 years in all countries of the world. For developing countries, urban and rural populations were considered separately
RESULTS: Prevalence of diabetes in adults worldwide was estimated to be 4.0% in 1995 and to rise to 5.4% by the year 2025. It is higher in developed than in developing countries. The number of adults with diabetes in the world will rise from 135 million in 1995 to 300 million in the year 2025. The major part of this numerical increase will occur in developing countries. There will be a 42% increase, from 51 to 72 million, in the developed countries and a 170% increase, from 84 to 228 million, in the developing countries. Thus, by the year 2025, >75% of people with diabetes will reside in developing countries, as compared with 62% in 1995. The countries with the largest number of people with diabetes are, and will be in the year 2025, India, China, and the U.S. In developing countries, the majority of people with diabetes are in the age range of 45-64 years. In the developed countries, the majority of people with diabetes are aged > or =65 years. This pattern will be accentuated by the year 2025. There are more women than men with diabetes, especially in developed countries. In the future, diabetes will be increasingly concentrated in urban areas.
CONCLUSIONS: This report supports earlier predictions of the epidemic nature of diabetes in the world during the first quarter of the 21st century. It also provides a provisional picture of the characteristics of the epidemic. Worldwide surveillance of diabetes is a necessary first step toward its prevention and control, which is now recognized as an urgent priority.

Entities:  

Mesh:

Year:  1998        PMID: 9727886     DOI: 10.2337/diacare.21.9.1414

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  1084 in total

Review 1.  Applications of economic models in healthcare: the introduction of pioglitazone in Sweden.

Authors:  Freddie Henriksson
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Comparing communication technology on Chinese, English, and Spanish diabetes web sites.

Authors:  Yanko F Michea; Karen Pancheri; Yang Gong; Elmer Bernstam
Journal:  Proc AMIA Symp       Date:  2002

Review 3.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 4.  Associations between single-nucleotide polymorphisms (+45T>G, +276G>T, -11377C>G, -11391G>A) of adiponectin gene and type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  L Y Han; Q H Wu; M L Jiao; Y H Hao; L B Liang; L J Gao; D G Legge; H Quan; M M Zhao; N Ning; Z Kang; H Sun
Journal:  Diabetologia       Date:  2011-06-03       Impact factor: 10.122

Review 5.  [Diabetic maculopathy and retinopathy. Functional and sociomedical significance].

Authors:  J G Garweg; A Wenzel
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

6.  Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes.

Authors:  S B Kristiansen; B Løfgren; N B Støttrup; D Khatir; J E Nielsen-Kudsk; T T Nielsen; H E Bøtker; A Flyvbjerg
Journal:  Diabetologia       Date:  2004-10-07       Impact factor: 10.122

Review 7.  Metabolic syndrome therapy: prevention of vascular injury by antidiabetic agents.

Authors:  Ligia J Dominguez; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

Review 8.  Dermatologic conditions associated with diabetes.

Authors:  Karen Nern
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

Review 9.  Obesity and sedentary lifestyle: modifiable risk factors for prevention of type 2 diabetes.

Authors:  E J Mayer-Davis; T Costacou
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

Review 10.  Clinical significance of glycated hemoglobin in the acute phase of ST elevation myocardial infarction.

Authors:  Chiara Lazzeri; Serafina Valente; Marco Chiostri; Maria Grazia D'Alfonso; Gian Franco Gensini
Journal:  World J Cardiol       Date:  2014-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.